Golden
Fate Therapeutics

Fate Therapeutics

A company developing therapies for the treatment of cancer and immune disorders

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders. Fate's cells of interest are the cells of the immune system. The company is headquartered in San Diego, California and was founded in 2007 by Rudolf Jaenisch.



They are also pioneering a novel approach to cell therapy by using renewable master induced pluripotent stem cell (iPSC) lines generated from the company's proprietary iPSC product platform to derive cell therapy products that can be delivered off-the-shelf for the treatment of a large number of patients.



Fate's cell therapy product pipeline comprises of immuno-oncology programs, including off-the-shelf NK- and T-cell products derived from the master iPSC lines, and immuno-regulatory programs, including products to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease.



The company's immuno-oncology pipeline is comprised of FATE-NK100, a donor derived natural killer (NK) cell cancer immunotherapy that is being evaluated in three Phase 1 clinical trials. Each of these trials focus on one of the following types of cancer, AML, ovarian, and solid tumors. Other products in the preclinical stage include iPSC-derived NK cell and T-cell immunotherapies, FT500, FT516, FT538, and FT819,



Fate's immuno-regulation pipeline on the other hand is comprised of ProTmune and ToleraCyte. ProTmune is a programmed cellular immunotherapy developed for patients with hematologic malignancies and rare genetic disorders that seek curative outcomes through hematopoietic cell transplantation (HCT). This next-generation donor cell graft that is being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. ToleraCyte is a pharmacologically programmed CD30+ cell therapy with potent immuno-regulatory properties being developed for the treatment of autoimmune and inflammatory diseases.

Timeline

Funding rounds

3 Results
Funding round
Funding round
Funded company
Funded company
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Alexander Rives

Founder



Bob Valamehr

Chief Development Officer



Cindy Tahl

General Counsel



Dan Shoemaker

Chief Scientific Officer



Jim Beitel

Senior VP, Corporate Development



John Mendlein

Vice Chairman



Scott Wolchko

President & CEO



Wen Bo Wang

Senior VP, Technical Operations



William Rastetter

Chairman



Further reading

Title
Author
Link
Type
Date

Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH

Arlene Weintraub

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References